Long-acting beta 2-adrenoceptor agonists or tiotropium bromide for patients with COPD: is combination therapy justified?

[1]  K. P. Hui,et al.  Modulation of neurally mediated airway microvascular leakage in guinea-pig airways byβ2 agonists , 1992, Agents and Actions.

[2]  S. Rennard.  COPD: treatments benefit patients , 2003, The Lancet.

[3]  R. Pauwels,et al.  Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial , 2003, The Lancet.

[4]  R. Sansores,et al.  Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease , 2003, European Respiratory Journal.

[5]  D. Mahler.  The effect of inhaled β2-agonists on clinical outcomes in chronic obstructive pulmonary disease , 2002 .

[6]  R. Dahl,et al.  Effects of salmeterol on mucosal inflammation in asthma: a placebo-controlled study , 2002, European Respiratory Journal.

[7]  Malcolm W Johnson.  Effects of beta2-agonists on resident and infiltrating inflammatory cells. , 2002, The Journal of allergy and clinical immunology.

[8]  I. Adcock,et al.  Molecular interactions between glucocorticoids and long-acting β2-agonists , 2002 .

[9]  J. van der Palen,et al.  Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. , 2002, American journal of respiratory and critical care medicine.

[10]  J. Yates,et al.  Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. , 2002, American journal of respiratory and critical care medicine.

[11]  P. Barnes,et al.  Tiotropium bromide: a novel once-daily anticholinergic bronchodilator for the treatment of COPD. , 2002, Drugs of today.

[12]  J. Vestbo,et al.  Can GOLD Stage 0 provide information of prognostic value in chronic obstructive pulmonary disease? , 2002, American journal of respiratory and critical care medicine.

[13]  E. Bateman,et al.  A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. , 2002, Chest.

[14]  M. Decramer,et al.  Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial , 2002, European Respiratory Journal.

[15]  J. V. van Noord,et al.  Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease , 2002, European Respiratory Journal.

[16]  G. Della Cioppa,et al.  Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. , 2002, Chest.

[17]  C. Billington,et al.  m3 muscarinic acetylcholine receptor regulation in the airway. , 2002, American journal of respiratory cell and molecular biology.

[18]  R. Zuwallack,et al.  A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease , 2002, European Respiratory Journal.

[19]  P. Rees.  Tiotropium in the management of chronic obstructive pulmonary disease , 2002, European Respiratory Journal.

[20]  J. V. van Noord,et al.  Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium , 2002, European Respiratory Journal.

[21]  R. Casaburi,et al.  Tiotropium bromide. Commentaries , 2002 .

[22]  G. D. Cioppa,et al.  Faster onset of bronchodilation with formoterol than with salmeterol in patients with stable, moderate to severe COPD: results of a randomized, double-blind clinical study. , 2002, Canadian respiratory journal.

[23]  D. Benhamou,et al.  Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk). , 2001, Respiratory medicine.

[24]  R. Dahl,et al.  Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.

[25]  S. Rennard,et al.  Alternative Mechanisms for Long-Acting β2-Adrenergic Agonists in COPD , 2001 .

[26]  D. Mahler,et al.  Effectiveness of salmeterol versus ipratropium bromide on exertional dyspnoea in COPD. , 2001, The European respiratory journal.

[27]  R. Zuwallack,et al.  Salmeterol plus theophylline combination therapy in the treatment of COPD. , 2001, Chest.

[28]  M. De Salvo,et al.  In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium : a 3-week, randomized, double-blind, within-patient, multicenter study. , 2001, Chest.

[29]  R. Zuwallack,et al.  Use of a Long-acting Inhaled β2-Adrenergic Agonist, Salmeterol Xinafoate, in Patients with Chronic Obstructive Pulmonary Disease , 2001 .

[30]  B. Disse.  Antimuscarinic treatment for lung diseases from research to clinical practice. , 2001, Life sciences.

[31]  M. Johnson.  Beta2-adrenoceptors: mechanisms of action of beta2-agonists. , 2001, Paediatric respiratory reviews.

[32]  D. Postma,et al.  Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial , 2001, The Lancet.

[33]  M. Cazzola,et al.  Onset of action of single doses of formoterol administered via Turbuhaler in patients with stable COPD. , 2001, Pulmonary pharmacology & therapeutics.

[34]  M. Cazzola,et al.  Additive effects of salmeterol and fluticasone or theophylline in COPD. , 2000, Chest.

[35]  D. D. Briggs,et al.  The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group. , 2000, Chest.

[36]  S. Spencer,et al.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial , 2000, BMJ : British Medical Journal.

[37]  W. Hop,et al.  Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. , 2000, The European respiratory journal.

[38]  M. Littner,et al.  Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. , 2000, American journal of respiratory and critical care medicine.

[39]  J. V. van Noord,et al.  A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease , 2000 .

[40]  D. O’Donnell,et al.  Assessment of bronchodilator efficacy in symptomatic COPD: is spirometry useful? , 2000, Chest.

[41]  M. Cazzola,et al.  Influence of higher than conventional doses of oxitropium bromide on formoterol-induced bronchodilation in COPD. , 1999, Respiratory medicine.

[42]  M. Cazzola,et al.  Incremental benefit of adding oxitropium bromide to formoterol in patients with stable COPD. , 1999, Pulmonary pharmacology & therapeutics.

[43]  D. Postma,et al.  Long-Term Treatment with Inhaled Budesonide in Persons with Mild Chronic Obstructive Pulmonary Disease Who Continue Smoking , 1999 .

[44]  P. Lange,et al.  Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial , 1999, The Lancet.

[45]  L. Sichletidis,et al.  BRONCHODILATORY RESPONSES TO FORMOTEROL, IPRATROPIUM, AND THEIR COMBINATION IN PATIENTS WITH STABLE COPD , 1999, International journal of clinical practice.

[46]  S. Yancey,et al.  Efficacy of salmeterol xinafoate in the treatment of COPD. , 1999, Chest.

[47]  S. Campbell,et al.  For COPD a combination of ipratropium bromide and albuterol sulfate is more effective than albuterol base. , 1999, Archives of internal medicine.

[48]  L. Squassante,et al.  Efficacy, tolerability, and effects on quality of life of inhaled salmeterol and oral theophylline in patients with mild-to-moderate chronic obstructive pulmonary disease , 1998 .

[49]  D. O’Donnell,et al.  Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. , 1998, American journal of respiratory and critical care medicine.

[50]  P. Argyropoulou,et al.  Comparison of the effects of salmeterol and ipratropium bromide on exercise performance and breathlessness in patients with stable chronic obstructive pulmonary disease. , 1998, Respiratory medicine.

[51]  Proud,et al.  Intranasal salmeterol inhibits allergen‐induced vascular permeability but not mast cell activation or cellular infiltration , 1998, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[52]  M. Cazzola,et al.  Effects of formoterol, salmeterol or oxitropium bromide on airway responses to salbutamol in COPD. , 1998, The European respiratory journal.

[53]  P. Paggiaro,et al.  Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease , 1998, The Lancet.

[54]  A. Morice,et al.  An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) , 1997, The European respiratory journal.

[55]  P. Barnes,et al.  Prolonged effect of tiotropium bromide on methacholine-induced bronchoconstriction in asthma. , 1996, American journal of respiratory and critical care medicine.

[56]  S. Green,et al.  Sustained Activation of a G Protein-coupled Receptor via “Anchored” Agonist Binding , 1996, The Journal of Biological Chemistry.

[57]  M. Cazzola,et al.  A combination with clinical recommended dosages of salmeterol and ipratropium is not more effective than salmeterol alone in patients with chronic obstructive pulmonary disease. , 1996, Respiratory medicine.

[58]  B. Lipworth,et al.  Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease. , 1996, Thorax.

[59]  M. Belman,et al.  Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. , 1996, American journal of respiratory and critical care medicine.

[60]  F. Maesen,et al.  Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study Group. , 1995, The European respiratory journal.

[61]  M. Yacoub,et al.  Effect of Ba 679 BR, a novel long-acting anticholinergic agent, on cholinergic neurotransmission in guinea pig and human airways. , 1994, American journal of respiratory and critical care medicine.

[62]  W. Bailey,et al.  Effects of Smoking Intervention and the Use of an Inhaled Anticholinergic Bronchodilator on the Rate of Decline of FEV1 , 1994 .

[63]  E. Tagaya,et al.  Effect of long term treatment with oxitropium bromide on airway secretion in chronic bronchitis and diffuse panbronchiolitis. , 1994, Thorax.

[64]  P. Barnes,et al.  Characterization of [3H]Ba 679 BR, a slowly dissociating muscarinic antagonist, in human lung: radioligand binding and autoradiographic mapping. , 1994, Molecular pharmacology.

[65]  K. Rabe,et al.  Why are long-acting beta-adrenoceptor agonists long-acting? , 1994, The European respiratory journal.

[66]  F. Maesen,et al.  Ba 679 Br, a new long-acting antimuscarinic bronchodilator: a pilot dose-escalation study in COPD. , 1993, The European respiratory journal.

[67]  B. Disse,et al.  Ba 679 BR, a novel long-acting anticholinergic bronchodilator. , 1993, Life sciences.

[68]  J. Earis,et al.  Acute bronchodilator trials in chronic obstructive pulmonary disease. , 1992, The American review of respiratory disease.

[69]  C. Persson,et al.  Pharmacologic control of plasma exudation into tracheobronchial airways. , 1991, The American review of respiratory disease.

[70]  H. Kuo,et al.  Neural control of goblet cell secretion in guinea pig airways. , 1990, The American journal of physiology.